Amgen UK’s Chris Fox: Up for the Challenge
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
Address: Boehringer Ingelheim Limited, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS, United Kingdom ,United Kingdom
Tel: +44 (0) 1344 424 600
Web: http://www.boehringer-ingelheim.co.uk/
Boehringer Ingelheim is a family owned company whose distinctly independent structure means that we are not constrained by the short-term needs of individual shareholders and can focus on the future with long-term strategies of vision and leadership. Boehringer Ingelheim was founded in 1885 by Albert Boehringer and remains a familyowned company. Today we are the fastest growing company amongst the world’s 15 leading pharmaceutical companies.
Annual sales are €12.7 billion worldwide (2009) and 21% of the net sales from its Prescription Medicine business is invested into research and development. The company now employ more than 41,500 people and is committed to remaining family-owned. Albert’s great grandson, Christian Boehringer, is the Chair of the Shareholders’ Committee which manages 142 affiliated companies in 50 countries around the globe. Our headquarters remain in Ingelheim, near Frankfurt in Germany.
Boehringer Ingelheim’s vision, ‘Value through Innovation’, mirrors the founder’s own belief in the importance of innovative thinking and that, as well as being financially profitable, products should be pioneering and of genuine benefit to patients. This independent status frees the company from stock market expectations, and allows for long-term strategies, rather than short-term priorities.
In the United Kingdom, Boehringer Ingelheim was established in 1962 and is one of the fastest growing pharmaceutical companies in the UK, with total sales of £388 million in 2009 (independent audit). The business focuses on clinical research, data management, sales and marketing.
Boehringer Ingelheim is involved in three key healthcare areas: Prescription Medicines, Over-The-Counter (OTC) products and Animal Health. In each sector, the company has world-class medicines to treat patients.
The company has a reputation for providing effective products for the treatment of chronic obstructive pulmonary disease (COPD), heart attack, secondary stroke prevention and treatment, high blood pressure, thromboembolic disease, HIV/AIDS, Parkinson’s disease, arthritis and pain relief in cancer.
These products are supported by a wide range of services, designed to help the medical profession deliver the best possible healthcare to patients.
This underlines Boehringer Ingelheim’s commitment to improving health and quality of life in the UK.
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO,…
Jonny Ohlson, founder & CEO of Touchlight, discusses the genetic medicine revolution and the role of Touchlight in disrupting the field with its revolutionary DNA technology. You founded Touchlight Genetics…
Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of…
KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united…
Sterling Pharma Solutions is a rapidly growing GMP contract API manufacturer based out of Dudley, Cramlington in the Northeast of England. The company was set up in its current structure…
Offering genomic sequencing and analysis, Congenica operates in the exciting world of genomic diagnosis, with a particular focus on rare diseases. Its CEO David Atkins describes the potential of Congenica’s…
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and…
See our Cookie Privacy Policy Here